Showing 981-990 of 1211 results for "".
- Sydnexis Announces Three Abstracts Accepted for Poster Presentations at ARVOhttps://modernod.com/news/sydnexis-announces-three-abstracts-accepted-for-poster-presentations-at-arvo/2482780/Sydnexis announced that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting taking place from May 4 to 8 in Salt Lake City. These posters present clinical data related to the STAR Study
- Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresseshttps://modernod.com/news/astellas-to-present-new-data-in-geographic-atrophy-at-upcoming-ophthalmology-annual-congresses/2482775/Astellas Pharma will highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, U
- Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology-conferences/2482774/Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Stud
- Nanoscope to Present New Data for Optogenetic Therapy for RP at Eyecelerator and ARVOhttps://modernod.com/news/nanoscope-to-present-new-data-for-optogenetic-therapy-for-rp-at-eyecelerator-and-arvo/2482769/Nanoscope Therapeutics announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010
- FDA Expands Luminopia's Label to Include Patients 8 to 12 with Amblyopiahttps://modernod.com/news/fda-expands-luminopias-label-to-include-patients-8-to-12-with-amblyopia/2482768/Luminopia announced that the FDA has cleared its amblyopia treatment for patients aged 8 to 12 years, expanding its existing label from patients 4 to 7 years old with amblyopia associated with anisometropia and/or mild strabismus. The expanded label opens the door to a new treatment opt
- Surgilūm's RoboMarker G2 Receives 5 International Medical Device Design Awardshttps://modernod.com/news/surgilums-robomarker-g2-receives-5-international-medical-device-design-awards/2482638/Surgilūm's RoboMarker G2 was awarded international medical device design awards by 3 associations. The awards include: New York Product Design Award: an international competition celebrating excellence in product desi
- FDA Clears ViGeneron's IND for Novel mRNA Gene Therapy to Treat Stargardt Disease and Other Retinal Dystrophieshttps://modernod.com/news/fda-clears-vigenerons-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/2482585/ViGeneron announced that the FDA has cleared the investigational new drug (IND) application for the phase 1/2 study of VG801, a gene therapy candidate to treat Stargardt disease and other retinal dystrophies associated with mutations in the&n
- Sepul Bio Announces First Patient Dosed in Trial Using Ultevursen for RPhttps://modernod.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/Sepul Bio announced the first person has been dosed for the LUNA clinical study, a phase 2b trial using ultevursen for USH2A-associated retinitis pigmentosa (RP). USH2A, or Usher Syndrome type 2a, is the most common cause of autosomal recessive retinitis pigmentosa that affec
- AOAExcel Endorses Its First EHR System: Barti Softwarehttps://modernod.com/news/aoaexcel-endorses-its-first-ehr-system-barti-software/2482554/AOAExcel, a member-benefit and for-profit subsidiary of the American Optometric Association (AOA), has made a financial investment in Barti Software, a San Francisco-based eye care Electronic Health Records (EHR) company. In addition, AOAExcel has endorsed Barti Software, which is the first
- GenSight Biologics Publishes Meta-Analysis on Efficacy of Treatments for Leber Hereditary Optic Neuropathyhttps://modernod.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/GenSight Biologics announced the publication of a meta-analysis evaluating visual outcomes in patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation. This mutation, known as ND4-LHON, is the most common cause of the disease and is associated with the